Gamma-glutamyl transferase to aspartate aminotransferase ratio (GSR) predicts prognoses in patients with colorectal cancer with liver metastasis after microwave ablation.
Humans
Male
Female
gamma-Glutamyltransferase
/ blood
Colorectal Neoplasms
/ pathology
Liver Neoplasms
/ secondary
Retrospective Studies
Microwaves
/ therapeutic use
Middle Aged
Aspartate Aminotransferases
/ blood
Aged
Prognosis
Neoplasm Recurrence, Local
/ blood
Biomarkers, Tumor
/ blood
Risk Factors
Adult
Aged, 80 and over
Ablation Techniques
Aspartate aminotransferase
Colorectal cancer
Gamma-glutamyl transpeptidase
Liver metastasis
Microwave ablation
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
15
04
2024
accepted:
16
09
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
30
9
2024
Statut:
epublish
Résumé
Microwave ablation (MWA) is widely used to eliminate colorectal liver metastases (CRLM). However, the risk of tumor recurrence is difficult to predict due to lack of reliable clinical and biological markers. Elevation of gamma-glutamyl transferase (GGT) and aspartate transaminase (AST) provides signals for liver inflammation and cancer progression. The present study evaluated the association between pre-ablation GGT to AST ratio index (GSR) and hepatic recurrence in patients with CRLM after MWA. A retrospectively analyzed 192 CRLM patients who underwent MWA from January 2013 to December 2017. Pre-ablation GSR was classified into high (≤ 2.34) or low (> 2.34) using the upper quartile value. The prognostic value of GSR and other risk factors for liver progression-free survival (LPFS) and cancer-specific survival (CSS) were evaluated by univariate and multivariate analyses. High GSR was significantly associated with males (P = 0.041), the presence of cholelithiasis (P = 0.012), but not pre-ablation chemotherapy (P = 0.355), which caused significantly increased levels of GGT (P = 0.015) and AST (P = 0.008). GSR showed a significant association with LPFS and CSS through univariate analysis (P = 0.002 and 0.006) and multivariate analysis (P = 0.043 and 0.037). The subgroup analysis demonstrated no interaction between GSR and all variables except for distribution in the sub-analysis of LPFS. Our findings suggest that the pre-ablation GSR can be considered as a promising prognostic indicator for poor prognosis of patients with CRLM underwent MWA. Not applicable.
Sections du résumé
BACKGROUND
BACKGROUND
Microwave ablation (MWA) is widely used to eliminate colorectal liver metastases (CRLM). However, the risk of tumor recurrence is difficult to predict due to lack of reliable clinical and biological markers. Elevation of gamma-glutamyl transferase (GGT) and aspartate transaminase (AST) provides signals for liver inflammation and cancer progression. The present study evaluated the association between pre-ablation GGT to AST ratio index (GSR) and hepatic recurrence in patients with CRLM after MWA.
METHODS
METHODS
A retrospectively analyzed 192 CRLM patients who underwent MWA from January 2013 to December 2017. Pre-ablation GSR was classified into high (≤ 2.34) or low (> 2.34) using the upper quartile value. The prognostic value of GSR and other risk factors for liver progression-free survival (LPFS) and cancer-specific survival (CSS) were evaluated by univariate and multivariate analyses.
RESULTS
RESULTS
High GSR was significantly associated with males (P = 0.041), the presence of cholelithiasis (P = 0.012), but not pre-ablation chemotherapy (P = 0.355), which caused significantly increased levels of GGT (P = 0.015) and AST (P = 0.008). GSR showed a significant association with LPFS and CSS through univariate analysis (P = 0.002 and 0.006) and multivariate analysis (P = 0.043 and 0.037). The subgroup analysis demonstrated no interaction between GSR and all variables except for distribution in the sub-analysis of LPFS.
CONCLUSIONS
CONCLUSIONS
Our findings suggest that the pre-ablation GSR can be considered as a promising prognostic indicator for poor prognosis of patients with CRLM underwent MWA.
TRIAL REGISTRATION
BACKGROUND
Not applicable.
Identifiants
pubmed: 39350076
doi: 10.1186/s12876-024-03419-0
pii: 10.1186/s12876-024-03419-0
doi:
Substances chimiques
gamma-Glutamyltransferase
EC 2.3.2.2
Aspartate Aminotransferases
EC 2.6.1.1
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
327Informations de copyright
© 2024. The Author(s).
Références
Li J, Liu G, Xie X, Zhang D, Zheng R, Yang H, et al. Outcomes Following Different Thermal Ablation Strategies in Patients with Unresectable Colorectal Liver Metastases. Radiology. 2023;308:e223135.
doi: 10.1148/radiol.223135
pubmed: 37581502
Tropea A, Biondi A, Corsaro A, Donati M, Basile F, Gruttadauria S. Combined microwave thermal ablation and liver resection for single step treatment of otherwise unresectable colorectal liver metastases; a monoistitutional experiences. Eur Rev Med Pharmacol Sci. 2014;18(2 Suppl):6–10.
pubmed: 25535184
Stattner S, Primavesi F, Yip VS, Jones RP, Ofner D, Malik HZ, et al. Evolution of surgical microwave ablation for the treatment of colorectal cancer liver metastasis: review of the literature and a single centre experience. Surg Today. 2015;45:407–15.
doi: 10.1007/s00595-014-0879-3
pubmed: 24633931
Ruers T, Van Coevorden F, Punt CJA, Pierie J-PEN, Borel-Rinkes I, Ledermann JA, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017;109:djx015.
doi: 10.1093/jnci/djx015
pubmed: 28376151
pmcid: 5408999
Eng OS, Tsang AT, Moore D, Chen C, Narayanan S, Gannon CJ, et al. Outcomes of microwave ablation for colorectal cancer liver metastases: a single center experience. J Surg Oncol. 2015;111:410–3.
doi: 10.1002/jso.23849
pubmed: 25557924
Wang J, Liang P, Yu J, Yu MA, Liu F, Cheng Z, et al. Clinical outcome of ultrasound-guided percutaneous microwave ablation on colorectal liver metastases. Oncol Lett. 2014;8:323–6.
doi: 10.3892/ol.2014.2106
pubmed: 24959270
pmcid: 4063642
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18 discussion 318–21.
doi: 10.1097/00000658-199909000-00004
pubmed: 10493478
pmcid: 1420876
Sasaki K, Morioka D, Conci S, Margonis GA, Sawada Y, Ruzzenente A, et al. The Tumor Burden Score: A New, “Metro-ticket” Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors. Ann Surg. 2018;267:132–41.
doi: 10.1097/SLA.0000000000002064
pubmed: 27763897
Cheung YS, Chan HL, Wong J, Lee KF, Poon TC, Wong N, et al. Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. Asian J Surg. 2008;31:41–9.
doi: 10.1016/S1015-9584(08)60056-1
pubmed: 18490213
Matias M, Casa-Nova M, Faria M, Pires R, Tato-Costa J, Ribeiro L, et al. Prognostic Factors after Liver Resection for Colorectal Liver Metastasis. Acta Med Port. 2015;28:357–69.
doi: 10.20344/amp.4816
pubmed: 26421789
Huang J, Cui W, Xie X, Lin K, Jin D, Xie X, et al. A novel prognostic model based on AFP, tumor burden score and albumin-bilirubin grade for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Int J Hyperthermia. 2023;40:2256498.
doi: 10.1080/02656736.2023.2256498
pubmed: 37733400
Zhang J, Guo G, Li T, Guo C, Han Y, Zhou X. Long-term survival analysis of ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma conforming to the milan criteria: Primary versus recurrent HCC. Int J Hyperthermia. 2024;41:2318829.
doi: 10.1080/02656736.2024.2318829
pubmed: 38467417
Tang X, Wang Q, Jin R, Hu C. A novel nomogram to predict prognosis in elderly early-stage hepatocellular carcinoma patients after ablation therapy. J Hepatocell Carcinoma. 2024;11:901–11.
doi: 10.2147/JHC.S459250
pubmed: 38774590
pmcid: 11107941
Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38:263–355.
doi: 10.1080/20014091084227
pubmed: 11563810
Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol. 2021;13:1688–98.
doi: 10.4254/wjh.v13.i11.1688
pubmed: 34904038
pmcid: 8637680
Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG. Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin Chem. 2002;48:1426–31.
doi: 10.1093/clinchem/48.9.1426
pubmed: 12194918
Rahmioglu N, Andrew T, Cherkas L, Surdulescu G, Swaminathan R, Spector T, et al. Epidemiology and genetic epidemiology of the liver function test proteins. PLoS ONE. 2009;4:e4435.
doi: 10.1371/journal.pone.0004435
pubmed: 19209234
pmcid: 2636884
Lee D-H, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38:535–9.
doi: 10.1080/10715760410001694026
pubmed: 15346644
Sookoian S, Pirola CJ. Alanine and aspartate aminotransferase and glutamine-cycling pathway: Their roles in pathogenesis of metabolic syndrome. World J Gastroenterol. 2012;18:3775–81.
doi: 10.3748/wjg.v18.i29.3775
pubmed: 22876026
pmcid: 3413046
Badmus OO, Hillhouse SA, Anderson CD, Hinds TD, Stec DE. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): Functional analysis of lipid metabolism pathways. Clin Sci (Lond). 2022;136:1347–66.
doi: 10.1042/CS20220572
pubmed: 36148775
Desjardin M, Bonhomme B, Le Bail B, Evrard S, Brouste V, Desolneux G, et al. Hepatotoxicities Induced by Neoadjuvant Chemotherapy in Colorectal Cancer Liver Metastases: Distinguishing the True From the False. Clin Med Insights-Oncol. 2019;13:1179554918825450.
doi: 10.1177/1179554918825450
pubmed: 30718969
pmcid: 6348554
Xiao B, Peng J, Tang J, Deng Y, Zhao Y, Wu X, et al. Serum Gamma Glutamyl transferase is a predictor of recurrence after R0 hepatectomy for patients with colorectal cancer liver metastases. Ther Adv Med Oncol. 2020;12:1758835920947971.
doi: 10.1177/1758835920947971
pubmed: 32913447
pmcid: 7444105
He WZ, Guo GF, Yin CX, Jiang C, Wang F, Qiu HJ, et al. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Dis. 2013;15:e443–52.
doi: 10.1111/codi.12258
pubmed: 23621885
Seebacher V, Polterauer S, Grimm C, Rahhal J, Hofstetter G, Bauer E-M, et al. Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: A multi-centre trial. Br J Cancer. 2012;106:1551–5.
doi: 10.1038/bjc.2012.16
pubmed: 22315051
pmcid: 3341855
Corti A, Belcastro E, Dominici S, Maellaro E, Pompella A. The dark side of gamma-glutamyltransferase (GGT): Pathogenic effects of an ‘antioxidant’ enzyme. Free Radical Biol Med. 2020;160:807–19.
doi: 10.1016/j.freeradbiomed.2020.09.005
Reuter S, Schnekenburger M, Cristofanon S, Buck I, Teiten M-H, Daubeuf S, et al. Tumor necrosis factor alpha induces gamma-glutamyltransferase expression via nuclear factor-kappaB in cooperation with Sp1. Biochem Pharmacol. 2009;77:397–411.
doi: 10.1016/j.bcp.2008.09.041
pubmed: 18996094
Tang K-S, Huang L-T, Huang Y-H, Lai C-Y, Wu C-H, Wang S-M, et al. Gamma-glutamyl transferase in the diagnosis of biliary atresia. Acta Paediatr Taiwan. 2007;48:196–200.
pubmed: 18265540
Wang Q, Chen Q, Zhang X, Lu XL, Du Q, Zhu T, et al. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2019;25:5515–29.
doi: 10.3748/wjg.v25.i36.5515
pubmed: 31576097
pmcid: 6767977
Peng S, Huang P, Yu H, Wen Y, Luo Y, Wang X, et al. Prognostic value of carcinoembryonic antigen level in patients with colorectal cancer liver metastasis treated with percutaneous microwave ablation under ultrasound guidance. Medicine. 2018;97:e0044.
doi: 10.1097/MD.0000000000010044
pubmed: 29517661
pmcid: 5882454
Qin S, Hu H, Cui R, Lin J, Liu Y, Wang Y, et al. A prognostic nomogram for intrahepatic progression-free survival in patients with colorectal liver metastases after ultrasound-guided percutaneous microwave ablation. Int J Hyperthermia. 2022;39:144–54.
doi: 10.1080/02656736.2021.2023226
pubmed: 35012413
Murata J, Ricciardi-Castagnoli P, Dessous L’Eglise Mange P, Martin F, Juillerat-Jeanneret L. Microglial cells induce cytotoxic effects toward colon carcinoma cells: measurement of tumor cytotoxicity with a gamma-glutamyl transpeptidase assay. Int J Cancer. 1997;70:169–74.
doi: 10.1002/(SICI)1097-0215(19970117)70:2<169::AID-IJC6>3.0.CO;2-V
pubmed: 9009156
Gong Z, Zhang X, Geng Q, Li W, Huang M, Chen Z, et al. AKP and GGT level can provide an early prediction of first-line treatment efficacy in colorectal cancer patients with hepatic metastases. Biomark Med. 2021;15:697–713.
doi: 10.2217/bmm-2020-0667
pubmed: 34169734
Mitrić A, Castellano I. Targeting gamma-glutamyl transpeptidase: A pleiotropic enzyme involved in glutathione metabolism and in the control of redox homeostasis. Free Radic Biol Med. 2023;208:672–83.
doi: 10.1016/j.freeradbiomed.2023.09.020
pubmed: 37739139
Di Ciaula A, Wang DQ-H, Portincasa P. Cholesterol cholelithiasis: Part of a systemic metabolic disease, prone to primary prevention. Expert Rev Gastroenterol Hepatol. 2019;13:157–71.
doi: 10.1080/17474124.2019.1549988
pubmed: 30791781
Castro J, Amigo L, Miquel JF, Gälman C, Crovari F, Raddatz A, et al. Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology. 2007;45:1261–6.
doi: 10.1002/hep.21616
pubmed: 17464999
Wang HH, Liu M, Clegg DJ, Portincasa P, Wang DQ-H. New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation. Biochim Biophys Acta. 2009;1791:1037–47.
doi: 10.1016/j.bbalip.2009.06.006
pubmed: 19589396
pmcid: 2756670
Manolaki AG, Larcher VF, Mowat AP, Barrett JJ, Portmann B, Howard ER. The prelaparotomy diagnosis of extrahepatic biliary atresia. Arch Dis Child. 1983;58:591–4.
doi: 10.1136/adc.58.8.591
pubmed: 6137197
pmcid: 1628309
Chen L, Fan Z, Sun X, Qiu W, Mu W, Chai K, et al. Examination on the risk factors of cholangiocarcinoma: A mendelian randomization study. Front Pharmacol. 2022;13: 900424.
doi: 10.3389/fphar.2022.900424
pubmed: 36091764
pmcid: 9462706
Guo L, Mao J, Li Y, Jiao Z, Guo J, Zhang J, et al. Cholelithiasis, cholecystectomy and risk of hepatocellular carcinoma: A meta-analysis. J Cancer Res Ther. 2014;10:834–8.
doi: 10.4103/0973-1482.135992
pubmed: 25579515
Pan S-Y, Zhou C-B, Deng J-W, Zhou Y-L, Liu Z-H, Fang J-Y. The effects of pks+ escherichia coli and bile acid in colorectal tumorigenesis among people with cholelithiasis or cholecystectomy. J Gastroenterol Hepatol. 2024;39:868–79.
doi: 10.1111/jgh.16462
pubmed: 38220146
Peng J, Li L, Ning H, Li X. Association between cholelithiasis, cholecystectomy, and risk of breast and gynecological cancers: Evidence from meta-analysis and mendelian randomization study. Ann Hum Genet. 2024. https://doi.org/10.1111/ahg.12573 .
Li Y-D, Ren Z-J, Gao L, Ma J-H, Gou Y-Q, Tan W, et al. Cholelithiasis increased prostate cancer risk: Evidence from a case-control study and a meta-analysis. BMC Urol. 2022;22:160.
doi: 10.1186/s12894-022-01110-8
pubmed: 36192737
pmcid: 9528176
Ge Y, Jeong S, Luo G-J, Ren Y-B, Zhang B-H, Zhang Y-J, et al. Transarterial chemoembolization versus percutaneous microwave coagulation therapy for recurrent unresectable intrahepatic cholangiocarcinoma: Development of a prognostic nomogram. Hepatobiliary Pancreat Dis Int. 2020;19:138–46.
doi: 10.1016/j.hbpd.2020.02.005
pubmed: 32139295
Qiu S, Jin L, Yang D, Zhang D. Clinical application value of hepatitis B virus basal core promoter 1762/1764 and GGTII and GGT in patients with HBV-DNA-positive primary liver cancer. Medicine (Baltimore). 2023;102:e35699.
doi: 10.1097/MD.0000000000035699
pubmed: 37904480
Ekmen N, Akalin Ç, Akyildiz M. Predictive value of protein induced by absence of vitamin K absence or antagonist II, alpha-fetoprotein and gamma-glutamyltransferase/aspartate aminotransferase ratio for the diagnosis of hepatocellular carcinoma in transplantation candidates. Eur J Gastroenterol Hepatol. 2021;32:294–9.
doi: 10.1097/MEG.0000000000001884
pubmed: 32796360
Schmidt BC, Leiderer MT, Amin T, Viol F, Huber S, Henes FO, et al. Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors? Endocrine. 2023. https://doi.org/10.1007/s12020-023-03545-x .
doi: 10.1007/s12020-023-03545-x
pubmed: 37770647
pmcid: 10850195